drugset / Trial / NCT00814658

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

NCT00814658

Phase 4 Completed 22 enrolled Janssen-Cilag Farmaceutica Ltda.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the combination of galantamine with nimodipine in patients with mixed dementia on cognition and quality of life.

Timeline

Start
2008-06
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 24 mg Oral
Subject Nimodipine Small molecule 30 mg Oral

Indications